Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

Comparison of In-House Methods and Cobas BRAF V600 Mutation Assay in Melanoma Tumor Samples

25 februari 2016 uppdaterad av: Hoffmann-La Roche

Evaluation of Concordance Between the Methods Used in INCa Platforms and the Cobas® 4800 BRAF V600 Mutation Test for Detection of BRAF V600 Mutations in Melanoma in Real Life Setting

This non-interventional study will compare the Cobas BRAF V600 mutation assay with in-house methods used in molecular laboratories for the assessment of the BRAF mutation status in melanoma tumor samples. No patients will be enrolled in this study. Data will be collected for approximately 6 months.

Studieöversikt

Status

Avslutad

Betingelser

Studietyp

Observationell

Inskrivning (Faktisk)

420

Kontakter och platser

Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.

Studieorter

      • Boulogne Billancourt, Frankrike, 92104
      • Colmar, Frankrike, 68024
      • Lille, Frankrike, 59037
      • Lyon, Frankrike, 69437
      • Marseille, Frankrike, 13015
      • Montpellier, Frankrike, 34295
      • Nantes, Frankrike, 44093
      • Paris, Frankrike, 75010
      • Pessac, Frankrike, 33604
      • Rouen, Frankrike, 76031
      • Vandoeuvre Les Nancy, Frankrike, 54511
      • Villejuif, Frankrike, 94505

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

  • Barn
  • Vuxen
  • Äldre vuxen

Tar emot friska volontärer

Nej

Kön som är behöriga för studier

Allt

Testmetod

Sannolikhetsprov

Studera befolkning

No patients are enrolled in this study. Use of melanoma tumor samples.

Beskrivning

Inclusion Criteria:

No patients are enrolled. Use of tumor samples only.

  • Histologically proven melanoma tumor sample
  • Any type of tumor sample: biopsy or surgical specimen of primary tumor or metastasis
  • Tumor samples must be fixed and paraffin-embedded.

Exclusion Criteria:

No patients are enrolled. Use of tumor samples only.

  • Fixative unknown

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

Kohorter och interventioner

Grupp / Kohort
INCa molecular genetics laboratory "in-house" methods
BRAF V600 mutations were analysed using INCa (Institut National du Cancer [French National Cancer Institute]) molecular genetics laboratories using "in-house" methods
Cobas 4800 Mutation Test
BRAF V600 mutations were analysed using Cobas 4800 mutation test

Vad mäter studien?

Primära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
BRAF Mutation Status According to Cobas 4800 BRAF V600 Mutation Test vs. INCa Laboratories Molecular Genetics Laboratories
Tidsram: Up to 6 months
BRAF V600 mutation status was determined by INCa molecular laboratories "in-house" methods and Cobas 4800 BRAF V600 mutation test. Samples were analysed as V600 mutation, No V600 mutation and Non evaluable. Additionally, the type of V600 mutation (E, K, R, D, E2, other V600 mutation, not specified) was also evaluated only by INCa molecular laboratory "in-house" method.
Up to 6 months

Sekundära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Tumor Sample Characteristics-Type of Tumor Sample
Tidsram: Up to 6 months
The type of tumor sample used for evaluation of BRAF V600 mutation whether it was a biopsy or surgical specimen were reported
Up to 6 months
Tumor Sample Characteristics - Source of Tumor Sample
Tidsram: Up to 6 months
The source of tumor sample for BRAF V600 mutation detection whether taken from internal or external pathology laboratory were reported
Up to 6 months
Type of Pathology Laboratory Performing the Fixation or Embedding-Pre-analytical Method
Tidsram: Up to 6 months
The external or internal pathology laboratories involved in the process of fixation or embedding of the tumor sample was evaluated.
Up to 6 months
Time From Sampling to Fixation- Pre-analytical Method
Tidsram: Up to 6 months
Time taken from the sampling to the fixation of the tumor sample was reported in range of 0-2 hours, 2-6 hours, >6 hours and unknown. Number of samples falling in each of the class were reported.
Up to 6 months
Type of Fixative Used- Pre-analytical Method
Tidsram: Up to 6 months
The different types of fixative Excell, formol, alcohol formol acetic acid and other, used to fix the tumor samples were reported.
Up to 6 months
Fixation Duration by Pre-analytical Method
Tidsram: Up to 6 months
Fixation duration is defined as the amount of time required in hours for the fixation of a samples. The fixation duration was categorized as <6 hours, 6-24 hours and >24 hours and unknown. Number of samples falling in each category were reported
Up to 6 months
Slice Thickness by Pre-analytical Method
Tidsram: Up to 6 months
Slice thickness of all the tumour samples was measured. The slice thickness was measured in micrometer.
Up to 6 months
Dewaxing by Pre-analytical Method
Tidsram: Up to 6 Months
Dewaxing is a method to recover the DNA from samples. Dewaxing information was collected as "Yes, No or Missing"
Up to 6 Months
Necrosis Percentage Determination by Pre-analytical Method
Tidsram: Up to 6 months
The percentage of necrosis defined as the death of one or more cells in the analysed zone was reported.
Up to 6 months
Percentage of Tumor Cells by Pre-analytical Method
Tidsram: Up to 6 months
The percentage of tumor cells in the given tumor sample were reported.
Up to 6 months
Tumor Samples With Presence of Melanin by Pre-analytical Method
Tidsram: Up to 6 months
The tumor samples with presence of melanin were categorized as Important, Few, Medium and Absent.
Up to 6 months
DNA Extraction - Extraction Method by Pre-analytical Method
Tidsram: Up to 6 months
This method assessed DNA from the tumor samples was extracted by Automated method or Manual method.
Up to 6 months
Median DNA Elution Volume by Pre-analytical Method
Tidsram: Up to 6 months
Median DNA elution volume microliters [mcl] was reported.
Up to 6 months
Mean DNA Concentration by Pre-analytical Method
Tidsram: Up to 6 months
The DNA concentration in the tissue elute was measured in nanogram per microliter (ng/mcL).
Up to 6 months
Amount of DNA by Pre-analytical Method
Tidsram: Up to 6 months
The total DNA concentration extracted from the tissue was measured in nanogram (ng).
Up to 6 months
Size of Amplicons Used by "In-house" Analytical Method
Tidsram: Up to 6 months
The method described the size of amplicon used. It was measured in base pairs (bp).
Up to 6 months
Method of Mutation Detection by "In-house" Analytical Method
Tidsram: Up to 6 months
Allele-specific PCR, High Resolution Melting (HRM) + Sanger sequencing, Pyrosequencing, Sanger sequencing, Real time PCR, SNaPshot were used for BRAF V600 mutation detection.
Up to 6 months
Number of Samples Punched in In-house Analytical Method
Tidsram: Up to 6 months
Total number of samples for whom punch was used in 'in-house analytical' method are reported.
Up to 6 months
Mean Number of Slices Per Sample Used for "In-house"- Analytical Method
Tidsram: Up to 6 months
The mean of number of slices per sample when no punch was used are reported.
Up to 6 months
Median Time Between Receipt of Samples and Determination of Result by "In-house" Analytical Method
Tidsram: Up to 6 months
This In-house analytical method measured the time between receipt of samples to the result determination. It measured the time in days.
Up to 6 months
Technician Work Time Between DNA Extraction and Result by "In-house" Analytical Method
Tidsram: Up to 6 months
The working time required by the technician from the time of DNA extraction to the time to obtain the results was measured in hours.
Up to 6 months
Mean DNA Concentration as Measured by COBAS 4800 BRAF V600 Mutation Test-Analytical Method
Tidsram: Up to 6 months
The DNA concentration as assessed by COBAS 4800 BRAF V600 Mutation assay was reported. The unit used to measure the DNA concentration was nanogram/microlitre (ng/mcl)
Up to 6 months
Punch Used for Cobas 4800 BRAF V600 Mutation Test- Analytical Method
Tidsram: Up to 6 months
The punch done during Cobas 4800 BRAF V600 Mutation Test on the sample was described as Yes or No.
Up to 6 months
Number of Slices Used When No Punch Was Used for Cobas 4800 BRAF V600 Mutation Test- Analytical Method
Tidsram: Up to 6 months
This describes the Cobas 4800 BRAF V600 Mutation Test, for the mean of number of slices when No punch method, was used. Of the 420 samples, punch was Yes, for 45 samples and punch was No, for 375 samples.
Up to 6 months
Median Time Between Receipt of Sample and Determination of Result by Cobas 4800 BRAF V600 Mutation Test -Analytical Method
Tidsram: Up to 6 months
This analytical method for cobas 4800 BRAF V600 Mutation Test measured the time between receipt of samples to the result determination. It measured the time in days.
Up to 6 months
Technician Work Time Between DNA Extraction and Result by Cobas 4800 BRAF V600 Mutation Test - Analytical Method
Tidsram: Up to 6 months
This cobas 4800 BRAF V600 Mutation Test analytical method measures the working time required by the technician from the time of DNA extraction to the time to obtain the results. The time duration was measured in hours.
Up to 6 months
Management of Discordance- Method Used to Manage Discordance
Tidsram: Up to 6 months
Crossing DNA, DNA from In-House method analysed with cobas, SNaPshot, DNA from cobas analysed with In-House method, external site control test, Sanger sequencing, Kit CE-IVD Therascreen RGQ Qiagen, Kit Therascreen RGQ BRAF + Pyrosequencing by another platform (PF), Pyrosequencing, Mutation detection On Another Block, (primitive tumor [prm. tmr]), Sequencing And Therascreen kit (Qiagen) were used for management of discordance between "in-house" method and Cobas 4800 mutation test.
Up to 6 months
Management of Discordance-Final Result for BRAF V600 Mutation Detection
Tidsram: Up to 6 months
The final results obtained by discordance management of the 28 discordant samples were BRAF V600 mutation, No BRAF V600 mutation and Non-evaluable. These results were further assessed by the Investigator and interpreted as final result.
Up to 6 months

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart

1 december 2012

Primärt slutförande (Faktisk)

1 april 2013

Avslutad studie (Faktisk)

1 april 2013

Studieregistreringsdatum

Först inskickad

6 december 2012

Först inskickad som uppfyllde QC-kriterierna

6 december 2012

Första postat (Uppskatta)

7 december 2012

Uppdateringar av studier

Senaste uppdatering publicerad (Uppskatta)

28 mars 2016

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

25 februari 2016

Senast verifierad

1 november 2015

Mer information

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .

Prenumerera